Hypertrophic Cardiomyopathy Diagnosis Series
CardioBites: Hypertrophic Cardiomyopathy Diagnosis
Hypertrophic cardiomyopathy (HCM) affects approximately 1 in 500 adults and is the most common cardiovascular genetic disorder. Many people don't realize they have this condition. In this CardioBites, we identify key indicators that help identify and diagnosis of HCM. Watch now
CardioBites: Comprehensive Management of Hypertrophic Cardiomyopathy Beyond Medical Therapy
Some individuals with hypertrophic cardiomyopathy don’t experience symptoms, while others can present with exertional dyspnea, fatigue, palpitations, lightheadedness, syncope, atypical chest pain, cardiac arrhythmias, or sudden cardiac death (SCD) related to ventricular diastolic dysfunction. This discussion looks at the key aspects of non-pharmacologic management, including red flags for sudden cardiac death, atrial fibrillation, family screening, and exercise. Watch now
CardioBites: Hypertrophic Cardiomyopathy: Disease Mechanisms in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is a genetic disorder that affects approximately 1 in 500 people. Some individuals with HCM don’t experience symptoms, while others can present with exertional dyspnea, fatigue, palpitations, lightheadedness, syncope, atypical chest pain, cardiac arrhythmias, or sudden cardiac death (SCD) related to ventricular diastolic dysfunction. In this CardioBites video, we explore how the pathogenesis and mechanisms of disease can facilitate effective, timely treatment for patients with HCM. We take a closer look at how both Familial and Non-Familial HCM can be classified as either obstructive or non-obstructive based on their presentation. Obstructive HCM (o-HCM) subtype of HCM has prevalence of 70% and non-obstructive HCM (n-HCM) is 30%. Familial HCM is present in 60% of the patient population with HCM by family history or genetic testing, and non-familial is 40%. Both familial and non-familial can present as O-HCM or n-HCM. Watch now
Future CardioBites:
CardioBites: Hypertrophic Cardiomyopathy: Pharmacologic Therapies for Hypertrophic Cardiomyopathy
Patients with hypertrophic cardiomyopathy (HCM) can have a multitude of symptoms, such as shortness of breath, chest pain, palpitations, fatigue, and fainting. Improving these symptoms is the main goal of treatment. In this CardioBites video, we explore the recent advances in first-line therapies such as beta blockers, calcium channel blockers, and the new cardiac myosin inhibitors that may invoke a paradigm shift in our treatment of HCM. Watch now!
Subscribe to the HFSA YouTube Channel